JP7123806B2 - 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ - Google Patents

静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ Download PDF

Info

Publication number
JP7123806B2
JP7123806B2 JP2018554361A JP2018554361A JP7123806B2 JP 7123806 B2 JP7123806 B2 JP 7123806B2 JP 2018554361 A JP2018554361 A JP 2018554361A JP 2018554361 A JP2018554361 A JP 2018554361A JP 7123806 B2 JP7123806 B2 JP 7123806B2
Authority
JP
Japan
Prior art keywords
cancer
cells
composition
inhibitor
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511554A5 (enExample
JP2019511554A (ja
Inventor
ビレンチク・マリア
フリッド・マイケル
クズネツォワ・アレクサンドラ
ガンキン・ユーリー
デューイ・マーク
Original Assignee
フェリシテックス・セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリシテックス・セラピューティクス，インコーポレイテッド filed Critical フェリシテックス・セラピューティクス，インコーポレイテッド
Publication of JP2019511554A publication Critical patent/JP2019511554A/ja
Publication of JP2019511554A5 publication Critical patent/JP2019511554A5/ja
Priority to JP2022126194A priority Critical patent/JP2022145800A/ja
Application granted granted Critical
Publication of JP7123806B2 publication Critical patent/JP7123806B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018554361A 2016-04-15 2017-04-14 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ Active JP7123806B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022126194A JP2022145800A (ja) 2016-04-15 2022-08-08 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
US62/323,537 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022126194A Division JP2022145800A (ja) 2016-04-15 2022-08-08 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ

Publications (3)

Publication Number Publication Date
JP2019511554A JP2019511554A (ja) 2019-04-25
JP2019511554A5 JP2019511554A5 (enExample) 2020-06-11
JP7123806B2 true JP7123806B2 (ja) 2022-08-23

Family

ID=60039950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554361A Active JP7123806B2 (ja) 2016-04-15 2017-04-14 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
JP2022126194A Pending JP2022145800A (ja) 2016-04-15 2022-08-08 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022126194A Pending JP2022145800A (ja) 2016-04-15 2022-08-08 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ

Country Status (11)

Country Link
US (3) US10322128B2 (enExample)
EP (1) EP3442505A4 (enExample)
JP (2) JP7123806B2 (enExample)
KR (2) KR20230020565A (enExample)
CN (1) CN109562176A (enExample)
AU (2) AU2017248762A1 (enExample)
BR (1) BR112018071031A2 (enExample)
CA (1) CA3021021A1 (enExample)
IL (2) IL262323B (enExample)
MX (2) MX2018012511A (enExample)
WO (1) WO2017181075A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009350A1 (en) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
CN109313197A (zh) 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
CN113557237B (zh) 2019-01-18 2025-01-14 沃若诺伊公司 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途
WO2020235973A1 (ko) * 2019-05-22 2020-11-26 주식회사 보로노이 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
JP2024523861A (ja) * 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
JP2017508763A (ja) 2014-03-20 2017-03-30 サミュメッド リミテッド ライアビリティ カンパニー ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
JP2018529639A (ja) 2015-07-23 2018-10-11 タイペイ・メディカル・ユニバーシティTaipei Medical University アミノナフトキノン化合物、および疾患におけるユビキチン化−プロテアソーム系をブロックするための薬学的組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
US10322128B2 (en) * 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
CN109313197A (zh) 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
JP2017508763A (ja) 2014-03-20 2017-03-30 サミュメッド リミテッド ライアビリティ カンパニー ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
JP2018529639A (ja) 2015-07-23 2018-10-11 タイペイ・メディカル・ユニバーシティTaipei Medical University アミノナフトキノン化合物、および疾患におけるユビキチン化−プロテアソーム系をブロックするための薬学的組成物

Also Published As

Publication number Publication date
CA3021021A1 (en) 2017-10-19
US11202779B2 (en) 2021-12-21
US20220110940A1 (en) 2022-04-14
KR20180132882A (ko) 2018-12-12
CN109562176A (zh) 2019-04-02
BR112018071031A2 (pt) 2019-02-12
MX2023000549A (es) 2023-02-13
IL262323A (en) 2018-11-29
KR20230020565A (ko) 2023-02-10
AU2017248762A1 (en) 2018-11-01
IL288777A (en) 2022-02-01
KR102494174B1 (ko) 2023-02-02
JP2019511554A (ja) 2019-04-25
IL262323B (en) 2022-03-01
US20190298723A1 (en) 2019-10-03
JP2022145800A (ja) 2022-10-04
MX2018012511A (es) 2019-07-08
US20170296541A1 (en) 2017-10-19
EP3442505A1 (en) 2019-02-20
US10322128B2 (en) 2019-06-18
EP3442505A4 (en) 2019-12-18
AU2023200428A1 (en) 2023-03-02
WO2017181075A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
JP7278776B2 (ja) 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ
RU2747788C2 (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
JP2019519573A (ja) がんを処置するための方法
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220810

R150 Certificate of patent or registration of utility model

Ref document number: 7123806

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150